Medicine and Dentistry
Radiation Therapy
100%
Melanoma
50%
Connective Tissue Cancer
48%
Diseases
42%
Soft Tissue Sarcoma
39%
Neoplasm
37%
Angiosarcoma
35%
Anal Cancer
31%
Chemoradiotherapy
26%
Overall Survival
25%
Drug Megadose
24%
Local Therapy
23%
Brachytherapy
23%
Immunotherapy
23%
Uterine Cancer
21%
Brain Metastasis
21%
Recurrent Disease
19%
Neck
16%
Preoperative Radiotherapy
16%
Hypofractionated Radiotherapy
15%
Scalp
15%
Mucosal Melanoma
15%
Malignant Neoplasm
14%
Primary Tumor
13%
Metastatic Carcinoma
12%
Hazard Ratio
12%
Systemic Therapy
12%
Squamous Cell Carcinoma
12%
Melanoma Cell
11%
Cancer
11%
Pelvis
9%
Quality of Life
9%
Lymphedema
9%
External Beam Radiotherapy
9%
Gastrointestinal Toxicity
9%
Wound Complication
8%
Arm
8%
Disease Exacerbation
7%
Metastatic Melanoma
7%
Neoadjuvant Therapy
7%
Intensity Modulated Radiation Therapy
7%
Carcinogenesis
7%
Disease Specific Survival
7%
Survival Rate
7%
Retroperitoneal Lymph Node Dissection
7%
Secretory Pathway
7%
Early Intervention
7%
Lymphocytopenia
7%
Retroperitoneal Sarcoma
7%
Lung Metastasis
7%
Keyphrases
Radiation Therapy
55%
Melanoma
38%
Local Control
37%
Anal Cancer
31%
Soft Tissue Sarcoma
27%
Sarcoma
24%
Overall Survival
24%
Local Therapy
24%
Cancer Patients
18%
Immune Checkpoint Inhibitors
17%
Head-and-neck
16%
Adjuvant Radiation Therapy
15%
Hypofractionated Radiation Therapy
15%
Neoadjuvant
15%
Intraoperative Radiation Therapy
15%
Multivariable
14%
Systemic Therapy
14%
Late Toxicity
14%
Brain Metastases
14%
Therapeutic Era
14%
Immune Checkpoint Blockade
14%
Surface Applicator
14%
Chemoradiation
14%
Radiation-induced Sarcoma
14%
Scalp
14%
Poor Outcome
14%
Endometrial Cancer
14%
Hazard Ratio
14%
Oncological Outcomes
12%
Pathological Response
10%
Completion Lymph Node Dissection
10%
Metastatic Melanoma
9%
Nodal Disease
9%
Surgery Therapy
9%
Metastatic Disease
9%
Disease-specific Survival
9%
Quality of Life
8%
Metastatic Sarcoma
8%
Mucosal Melanoma
8%
Response Rate
8%
Lymph Node Positive
8%
Large Cohort
8%
Sentinel Lymph Node Biopsy
8%
Progression-free Survival
8%
Targeted Therapy
8%
Event-free Survival
8%
Postoperative Radiotherapy
8%
Prognostic Features
8%
Lymphedema
8%
Disease Progression
7%